氧化应激与阿尔茨海默病以及抗氧化治疗研究进展

被引：17

作者：

付艳玲

薛寿儒

机构：

[1] 苏州大学附属第一医院神经内科

来源：

国际神经病学神经外科学杂志 | 2010年 / 37卷 / 04期

关键词：

活性氧自由基; 活性氮自由基; 氧化应激; 抗氧化剂; 阿尔茨海默;

D O I：

10.16636/j.cnki.jinn.2010.04.020

中图分类号：

R749.16 [];

学科分类号：

100203 ;

摘要：

氧化应激机制是导致阿尔茨海默病(AD)患者神经元变性及功能丧失的主要原因之一,它可与β淀粉样肽(Aβ)相互作用,激活信号通路而促进AD发生及进展,积极的抗氧化措施可预防、延缓、治疗AD。检测外周血氧化应激标志物可反映氧化应激水平及指导抗氧化治疗。目前应用的抗氧化剂包括生理性、天然、化学合成三类,其作用机制各有异同。本文综述了氧化应激与阿尔茨海默病关系以及抗氧化治疗的最新研究进展。

引用

页码：336 / 340

页数：5

共 17 条

[1] 阿尔茨海默病中的钙紊乱机制研究进展
陈艳杏
孙圣刚
[J]. 国际神经病学神经外科学杂志, 2009, 36 (05) : 441 - 444
[2] Oxidative Stress in the Progression of Alzheimer Disease in the Frontal Cortex
Ansari, Mubeen A.
Scheff, Stephen W.
[J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2010, 69 (02) : 155 - 167
[3] Proteomic identification of nitrated brain proteins in early Alzheimer's disease inferior parietal lobule
Reed, Tanea T.
Pierce, William M., Jr.
Turner, Delano M.
Markesbery, William R.
Butterfield, D. Allan
[J]. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2009, 13 (8B) : 2019 - 2029
[4] Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment
Mangialasche, Francesca
Polidori, M. Cristina
Monastero, Roberto
Ercolani, Sara
Camarda, Cecilia
Cecchetti, Roberta
Mecocci, Patrizia
[J]. AGEING RESEARCH REVIEWS, 2009, 8 (04) : 285 - 305
[5] Proteomic identification of HNE-bound proteins in early Alzheimer disease: Insights into the role of lipid peroxidation in the progression of AD[J] . Tanea T. Reed,William M. Pierce,William R. Markesbery,D. Allan Butterfield.Brain Research . 2009
[6] Protective effect of stilbenes containing extract-fraction from Cajanus cajan L. on Aβ 25–35 -induced cognitive deficits in mice[J] . Can-Jun Ruan,Jian-Yong Si,Li Zhang,Di-Hua Chen,Guan-Hua Du,Lan Sun.Neuroscience Letters . 2009 (2)
[7] Natural Antioxidants Protect Neurons in Alzheimer's Disease and Parkinson's Disease
Zhao, Baolu
[J]. NEUROCHEMICAL RESEARCH, 2009, 34 (04) : 630 - 638
[8] Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial[J] . Lars Lannfelt,Kaj Blennow,Henrik Zetterberg,Stellan Batsman,David Ames,John Harrison,Colin L Masters,Steve Targum,Ashley I Bush,Ross Murdoch,Janet Wilson,Craig W Ritchie.Lancet Neurology . 2008 (9)
[9] Effects of oxidative and nitrosative stress in brain on p53 proapoptotic protein in amnestic mild cognitive impairment and Alzheimer disease
Cenini, Giovanna
Sultana, Rukhsana
Memo, Maurizio
Butterfield, D. Allan
[J]. FREE RADICAL BIOLOGY AND MEDICINE, 2008, 45 (01) : 81 - 85
[10] Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from Mild Cognitive Impairment
Bermejo, Paloma
Martin-Aragon, Sagrario
Benedi, Juana
Susin, Cristina
Felici, Emanuela
Gil, Pedro
Ribera, Jose Manuel
Villar, Angel Ma
[J]. FREE RADICAL RESEARCH, 2008, 42 (02) : 162 - 170

← 1 2 →